Achieving long-term survival in BRAF mutation-positive melanoma in a rapidly-evolving therapeutic landscape – Royal Australasian College of Surgeons

After completing this module, participants will be better able to:

1. recall mechanisms of actions, indications, contra-indications, adverse effect (AE) profiles and Pharmaceutical Benefits Scheme (PBS) listing of novel targeted therapies for BRAF mutation-positive metastatic melanoma
2. evaluate clinical trial evidence on efficacy and safety of each novel targeted therapy, including monotherapy and combination therapy
3. discuss issues related to long-term survival: prognostic features, mutation type and resistance development
4. monitor and manage adverse events related to novel therapies and optimise health-related quality of life (HRQoL)